Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
BRISBANE, Calif., May 31, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a company overview at two investor conferences in early June.
Details of the presentations follow:
Primary Capital, The Investor Conference
Date: Sunday, June 4, 2017
Location: The Resort at Pelican Hill, Newport Beach, Calif.
7th Annual LD Micro Invitational
Date: Tuesday, June 6, 2017, 1:30 p.m. PT
Track: 5
Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.
In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at [email protected].
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
